Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4442756 | 0.99 | IDO1 (0.50) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| SCHEMBL3690757 | 0.94 | CYP1A2 (0.53) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| SCHEMBL3680100 | 0.94 | IDO1 (0.52) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| Bromide SCHEMBL4437753 | 0.93 | IDO1 (0.51) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| Bromide SCHEMBL4448810 | 0.93 | IDO1 (0.53) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| SCHEMBL3680878 | 0.90 | CYP1A2 (0.48) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| SCHEMBL3687833 | 0.87 | IDO1 (0.47) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| SCHEMBL3687166 | 0.87 | HPGD (0.42) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| Bromide SCHEMBL4442761 | 0.86 | HPGD (0.41) | CYP1A2HPGDCYP2D6CYP2C9ALOX15 | |
| SCHEMBL3691331 | 0.83 | IDO1 (0.52) | CYP1A2HPGDCYP2D6IDO1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | claimed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | claimed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | claimed |
| WO-2010005851-A1 | COMBINATION THERAPY FOR TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-01-14 | — | — | WO | disclosed |
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | CYP1A2 71/4885HPGD 575/4885CYP2D6 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.